These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6775302)

  • 41. [Echocardiographic study of the effects of a nitroglycerin microcapsule preparation (author's transl)].
    Drobinski G; Evans JL; Borel P; Thomas D; Bejean Lebuisson A; Grosgogeat Y
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2462-4. PubMed ID: 6775299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Electroplethysmographic study of nitroglycerin microcapsule preparation at two concentrations: 2.5 and 7.5 mg (author's transl)].
    Haïat R; Foulhoux P; Houri L; Halphen C; Desoutter P
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2470-2. PubMed ID: 6775300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Percutaneous nitroglycerin and its indications in intensive care. Apropos of 10 cases].
    Moine M
    Ann Cardiol Angeiol (Paris); 1983; 32(2):127-33. PubMed ID: 6416134
    [No Abstract]   [Full Text] [Related]  

  • 44. Hemodynamics and resting pulmonary gas exchange; effects of nitroglycerin ointment in patients with cardiomyopathy.
    Gould L; Reddy CV; Macklin EJ; Singh BK; Zen B
    N Y State J Med; 1980 Sep; 80(10):1549-52. PubMed ID: 6775253
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical pharmacology of tolmesoxide in refractory heart failure.
    O'Boyle CP; McGarry K; Fitzgerald D; Kelly JG; Horgan J; O'Malley K
    Eur J Clin Pharmacol; 1981; 21(3):169-72. PubMed ID: 7318877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Recent advances in the treatment of heart failure (author's transl)].
    Urbina-Quintana A
    Acta Cient Venez; 1978; 29(3):185-90. PubMed ID: 757728
    [No Abstract]   [Full Text] [Related]  

  • 47. Hazards associated with chest application of nitroglycerin ointments.
    Parke JD; Higgins SE
    JAMA; 1982 Jul; 248(4):427. PubMed ID: 6806492
    [No Abstract]   [Full Text] [Related]  

  • 48. [In vitro liberation of nitroglycerin from percutaneous galenical formulations. II].
    Pirotte B; Jaminet F
    J Pharm Belg; 1984; 39(2):77-87. PubMed ID: 6432993
    [No Abstract]   [Full Text] [Related]  

  • 49. [In vitro liberation of nitroglycerin from galenic formulations intended for percutaneous use. I].
    Pirotte B; Jaminet F
    J Pharm Belg; 1984; 39(1):23-35. PubMed ID: 6427442
    [No Abstract]   [Full Text] [Related]  

  • 50. Time required for solutions to flow through pulmonary artery catheters before entering the systemic circulation.
    Dasta JF
    Heart Lung; 1984 May; 13(3):320. PubMed ID: 6425242
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison between the hemodynamic effects of nitroglycerine ointment and oral isosorbide dinitrate in the treatment of left ventricular failure (author's transl)].
    Mauri F; Mafrici A; Azzollini M; Maggiulli G; Domenichini R
    G Ital Cardiol; 1981; 11(12):2070-80. PubMed ID: 6809518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early and medium term results of tailored therapy for heart failure.
    Martins S; Soares RM; do Rosário L; Quininha J; Antunes AM
    Rev Port Cardiol; 2001 Mar; 20(3):261-82. PubMed ID: 11417309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous nitroglycerin and cardiac failure.
    Gould LA
    N Y State J Med; 1984 Mar; 84(3 Pt 1):136-9. PubMed ID: 6425746
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment of left ventricular failure with percutaneous nitroglycerin (author's transl)].
    Lancelin B; Guermonprez JL; Bonin M; Maurice P
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2478-82. PubMed ID: 6775302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hemodynamic effects of percutaneous trinitrin].
    Page A; Ledain L; Gateau P; Besse P
    Arch Mal Coeur Vaiss; 1981 Apr; 74(4):453-61. PubMed ID: 6786243
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Value of the replacement of intravenous trinitrin by oral trinitrin in the acute phase of myocardial infarction complicated by regressive left ventricular insufficiency].
    Gibelin P; Ferrari E; Tiger F; Morand P
    Ann Cardiol Angeiol (Paris); 1991 Sep; 40(7):447-51. PubMed ID: 1952777
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.